Klaria
Private Company
Funding information not available
Overview
Klaria is a private, clinical-stage biotech company pioneering a disruptive transmucosal drug delivery platform. Its core technology is an alginate-based film that adheres to the oral mucosa, delivering active pharmaceutical ingredients directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism. The company's strategy focuses on reformulating injectable drugs with poor oral bioavailability into convenient, patient-friendly films, with lead programs in migraine (sumatriptan) and anaphylaxis (epinephrine). Klaria aims to create superior, lower-cost products that can capture significant market share in multi-billion dollar therapeutic areas.
Technology Platform
Alginate-based buccal film for transmucosal drug delivery. The film adheres to the oral mucosa, delivering the active pharmaceutical ingredient directly into the bloodstream without being swallowed, bypassing the GI tract and first-pass metabolism.
Opportunities
Risk Factors
Competitive Landscape
Klaria competes with auto-injector manufacturers (e.g., Viatris, Kaleo) in anaphylaxis and with a broad range of migraine drug/formulation companies. Its key differentiator is the claim of true transmucosal delivery without swallowing, setting it apart from other oral/buccal films and sprays where significant GI absorption occurs. It faces competition from other non-invasive delivery technologies in development.